Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

AGC Biologics’ Seattle Site Achieves Successful Multi-Product Inspection by U.S. Food and Drug Administration for Biologics License Applications

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today that its Seattle Campus completed a new commercial milestone for regulatory compliance in 2024. The site supported a multi-product inspection in March 2024 with the Food and Drug Administration (FDA) to support Biologics License Applications (BLA) for new products seeking commercial approval in the U.S., two of which are now approved for commercial production at the facility. The two approved products include a fusion protein-based drug for treating bladder cancer and a monoclonal antibody (mAb) for treating macular degeneration. AGC Biologics Seattle predicts delivering multiple batches per year for the biopharma partners that received the approvals and accommodating increases in future demand. “This achievement is significant for this site, our team members and our partners in the pharmaceutical industry seeking to bring products from clinical stages to commercial approval,” notes Michael Tranmer, General Manager of AGC Biologics Seattle. “Inspections for multiple products at one time is not easy. This accomplishment is a true testament to our commitment to quality and regulatory compliance and helping developers reach their goals as fast and efficiently as possible.” This is the latest achievement for the Seattle-based CDMO manufacturing site, which has produced six commercial products for AGC Biologics. This includes three commercial approvals in the last two years. AGC Biologics Seattle is active in helping clients navigate clinical milestones, as well. The site team is working with several clinical-stage companies and predicts more commercial license application submissions in the coming 18 to 24 months. AGC Biologics runs multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle site. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes. Over the last year, AGC Biologics Seattle has also expanded. This work includes a new microbial-based manufacturing line system and a state-of-the-art 67,000 sq. ft. GMP-compliant warehouse to further enhance the quality, efficiency and operational excellence of the site. To learn more about AGC Biologics’ protein biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s end-to-end global CDMO services in the U.S., Europe, and Japan visit www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

July 29, 2024 05:30 AM Pacific Daylight Time

BestGrowthStocks.Com Issues a Comprehensive Analysis of Tivic Health Systems Potential Catalysts

Tivic Health Systems Inc.

NEW YORK, NY / NewsDirect / July 29, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis on Tivic Health Systems Inc. a health tech company that develops and commercializes bioelectronic medicine. Tivic Health Systems Inc. (NASDAQ: TIVC) recently announced the expansion of its intellectual property portfolio with three new patents granted in the US and Europe. Best Growth Stocks full report breaks through the noise and offers an extensive comprehensive analysis of Tivic Health Systems operations, potential catalysts, pipeline, patents, share structure, recent news events, growth strategy, financials, chart support and resistance zones, and more. Access this full analysis free here: https://bestgrowthstocks.com/access-tivc-analysis/ Access the full analysis free here: https://bestgrowthstocks.com/access-tivc-analysis/ About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.com Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com

July 29, 2024 04:25 AM Eastern Daylight Time

Image

Benchmark International Successfully Facilitated the Transaction Between Mideast Delivery Solutions and SPS Health

Benchmark International

Benchmark International is pleased to announce the successful transaction between Mideast Delivery Solutions and SPS Health. The seller, Mideast Delivery Solutions, was established in 2014 and quickly became a leader in providing the timely and secure delivery of pharmaceuticals and critical healthcare supplies in their respective markets. Based in Mason, Ohio, the company specializes in servicing long-term care pharmacies, ensuring reliable and efficient deliveries tailored to the specific needs of their clients. Their services include daily delivery route coordination, STAT order coverage, and comprehensive consulting to optimize logistics. With a strong commitment to client satisfaction, they have earned the trust and respect of numerous healthcare providers over the years. Paul Hester, President of Mideast Delivery Solutions, had this to say about the transaction: "Matthew Kekelis, I want to thank you and your team for making an important process seem extremely smooth! A special thank you to Tyler Gonska for navigating me through the events! It was not an easy decision for me to go to market, but everyone at Benchmark International made each step of the way very comfortable. I highly recommend Benchmark International for any business!" The Buyer, SPS Health, is a leading provider of comprehensive solutions for healthcare providers in the acute care and post-acute marketplace. They offer an extensive portfolio of services and solutions for pharmacies, healthcare providers, and PBMs, including formulary management, on-demand pharmacy, and benefit administration. The company's focus on integrating advanced technologies ensures seamless operations, improved patient outcomes, and increased efficiency for healthcare providers. SPS will continue to prioritize exceptional customer service, innovations, and best-in-class technology with the addition of Mideast Delivery. "Paul with Mideast Delivery has built himself an incredible business and is turning over a well-oiled machine to SPS. We at Benchmark wish all the best to Paul in his future endeavors as well as SPS to continue Mideast's exceptional service." – Matthew Kekelis, Senior Director, Benchmark International Americas: Sam Smoot at +1 (813) 898 2350/ Smoot@BenchmarkIntl.com Europe: Michael Lawrie at +44 (0) 161 359 4400 / Lawrie@BenchmarkIntl.com Africa: Anthony McCardle at +27 21 300 2055 / McCardle@BenchmarkIntl.com ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

July 25, 2024 09:00 AM Eastern Daylight Time

Image

This Pharma Company Is Preparing To Launch Its Lead Candidate

Benzinga

By Johnny Rice, Benzinga Leonard Mazur, CEO and founder of Citius Pharmaceuticals (NASDAQ: CTXR), was recently interviewed by Benzinga. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, stem cell therapy, and unique prescription products. Mazur spoke about the exciting developments in the company’s assets, including the imminent launch of its first drug on the market. Learn more here: Featured photo by freestocks on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 25, 2024 08:58 AM Eastern Daylight Time

Video Image

Heat Stroke and Heat-Related Illness Rapidly Rising as Global Temperatures Climb

Centre for Neuro Skills

The number of people exposed to extreme heat has grown exponentially due to climate change, according to the World Health Organization. The New York Times reported that June 2024 was the 13 th consecutive month to break the global heat record. In 2023, 32 million people across California, Texas and Nevada experienced the hottest summer ever recorded in the United States. Centre for Neuro Skills (CNS), a leading provider of traumatic and acquired brain injury rehabilitation services with seven locations in California and Texas, shares essential tips for heat stroke prevention. Taking proactive measures to avoid heat stroke can be the difference between life and death. To avoid heat stroke: Dress in lightweight, loose-fitting clothing Apply sunscreen to avoid sunburn and keep the body cool Drink plenty of water and avoid sugary or alcoholic drinks Limit time outside to when it is cooler or if you must go out when temperatures are high, rest often Avoid leaving children or animals in parked cars, even if the windows are cracked open Monitor loved ones who are at high risk for developing heat stroke Check local news for extreme heat alerts “Of all the heat-related illnesses, heat stroke is the most serious. Heat stroke occurs when the body is no longer able to regulate temperature and cool down,” said Dr. Gary Seale, Regional Director of Clinical Services at CNS. “Body temperatures can rise rapidly to 104 degrees or higher which can cause damage to organs, including the brain, and result in permanent disability. Heat stroke can cause brain swelling, seizures, and lead to chronic inflammation, all of which disrupt brain function.” Children under 4 years old, adults over 65 years old with illnesses or medications that prevent body temperature regulation and people that are clinically classified as obese are all at higher risk of heat stroke. Heat exhaustion can be caused by engaging in strenuous activity, overexposure to hot weather and humidity and wearing excessive clothing that does not allow sweat to evaporate. Symptoms of heat stroke include high body core temperature, flushed skin, dizziness, loss of consciousness for longer than a few seconds, rapid heart rate, difficulty breathing, muscle cramps, seizures, vomiting and diarrhea. If you or a loved one are showing signs of heat stroke, call 911 immediately or transport the person to the hospital. While waiting for help, keep the person in a cool environment, remove unnecessary clothing and apply ice packs or cool water to their skin. ### About Centre for Neuro Skills Centre for Neuro Skills (CNS) is an experienced and respected world leader that provides intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced acquired and traumatic brain injury rehabilitation care, from residential and assisted living programs to outpatient rehabilitation, day treatment and telehealth services. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas and has been recognized by the American Stroke Association for its work in stroke rehabilitation. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Instagram, Facebook, X (formerly known as Twitter), LinkedIn, and YouTube. Media, please note: To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

July 23, 2024 08:01 AM Pacific Daylight Time

Classiq Transforms Quantum Computing with Qmod, The First High-Level Language for Quantum Programming

Classiq Technologies

Classiq today announced the general availability of Qmod (Quantum Modeling Language), the first high-level language (HLL) for quantum coding. Following successful pilot projects with enterprise partners, Qmod is now accessible to developers, researchers and enterprises worldwide and will transform quantum computing with its efficient, approachable method of programming. Qmod facilitates advanced quantum modeling and enables developers to describe quantum algorithms at a high level of abstraction. It supports unique quantum-computing concepts alongside conventional constructs found in high-level classical programming languages. This innovative approach allows developers to focus on the functional intent of their algorithms while Classiq’s powerful compiler and synthesis engine handle the intricate hardware-aware quantum implementation details. “To deliver a business or scientific value, quantum computing must be useful and accessible to scientists and engineers seeking to use quantum computing to solve real-world problems, which today it is not,” said Heather West, PhD, Research Manager, Quantum Computing at IDC. “Today, programming a quantum computer happens at the hardware level, making the technology only accessible to quantum physicists and other quantum specialists. As we begin to talk about quantum utility and near-term applications, abstraction-level application programming will become a necessity for wide-spread quantum adoption and usage.” Why The Qmod Language Is Different Declarative programming: Qmod’s declarative nature lets users define what their algorithm should achieve rather than how to achieve it; Classiq’s synthesis engine compiler optimizes for hardware and other constraints automatically. Flexibility and interoperability: Whether through native syntax, Python or graphical representation, Qmod descriptions are easily translatable and compatible across different formats and hardware. Industry-ready: Qmod is a tool for researchers and industry applications, providing robust scalable solutions for enterprise-grade quantum software development in an era of steadily growing qubit counts and the resulting coding complexity. “As we go further in building a complete quantum software stack, our groundbreaking Qmod language enables quantum experts to produce sophisticated programs while also allowing developers without a quantum background to innovate and solve complex problems across a variety of industry domains,” said Nir Minerbi, CEO and co-founder of Classiq. “By abstracting the complexities of quantum programming, Qmod delivers the ability to create and deploy dynamic quantum applications effortlessly. In some cases, it’ll use perhaps five lines of code instead of the traditional 100 lines of code. Like Java for the worldwide web or BASIC for PCs, Qmod is intended to open the gates to advanced quantum implementation.” Classiq’s platform ensures that quantum algorithms designed with Qmod can be seamlessly compiled for a broad range of hardware and simulation environments, as well as supporting seamless HPC integration. The platform's synthesis engine dynamically adapts implementations to different hardware configurations, allowing for rapid benchmarking and ensuring optimal implementations that make the very most of the available hardware. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC, and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and https://www.classiq.io to learn more. Contact Details Rainier Communications Michelle Allard McMahon classiqPR@rainierco.com Company Website http://www.classiq.io/

July 23, 2024 08:00 AM Eastern Daylight Time

Image

Classiq and QuEra Announce Integration of Neutral-Atom Quantum Computers into Classiq Platform

Classiq Technologies

Classiq, the leader in quantum software development, and QuEra Computing, the leader in neutral-atom quantum computing, today announced a strategic collaboration to integrate QuEra’s cutting-edge neutral-atom quantum computers into the Classiq platform. This integration will enable customers to optimize a wide variety of quantum and hybrid quantum/classical algorithms for QuEra’s quantum computers, leveraging the unique capabilities of QuEra’s advanced quantum technology. With this collaboration, Classiq users will be able to exploit the distinctive features of QuEra’s neutral-atom quantum computers, such as the ability to simultaneously operate on multiple qubits and advanced qubit shuttling. Additionally, the integration provides access to Classiq’s extensive pre-written algorithmic blocks and allows customers to estimate the resources needed to run their algorithms. These capabilities enable the creation of highly resource-efficient algorithms with a large number of qubits and, in the future, for logical qubits as well. “Our partnership with QuEra represents a significant step forward in the quantum computing landscape,” said Nir Minerbi, CEO of Classiq. “By integrating QuEra’s neutral-atom technology into our platform, we are providing our users with unprecedented opportunities to enhance and optimize their quantum algorithms. This collaboration underscores our commitment to delivering the most versatile and powerful quantum computing solutions available.” “We are thrilled to collaborate with Classiq and bring the power of our neutral-atom quantum computers to a broader audience,” said Yuval Boger, Chief Commercial Officer of QuEra. “Classiq’s platform is renowned for its ease of use and flexibility, and by integrating our technology, we can help users unlock new potential and achieve groundbreaking results in their quantum computing projects.” The integration of QuEra’s quantum computers into the Classiq platform is expected to accelerate the development and deployment of quantum applications across various fields, including pharmaceuticals, finance, logistics and more. Customers who have purchased on-premises computers will be able to use the Classiq platform for the rapid development of quantum algorithms. This partnership highlights the ongoing commitment of both companies to drive innovation and make quantum computing more accessible and impactful. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC, and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and https://www.classiq.io to learn more. About QuEra QuEra Computing is the leader in commercializing quantum computers using neutral atoms—widely recognized as a highly promising quantum modality. Based in Boston and built on pioneering research from nearby Harvard University and MIT, QuEra operates the world’s largest publicly accessible quantum computer, available over a major public cloud and for on-premises delivery. QuEra is developing large-scale, fault-tolerant quantum computers to tackle classically intractable problems, becoming the partner of choice in the quantum field. Simply put, QuEra is the best way to quantum. For more information, visit us at quera.com and follow us on X or LinkedIn. Contact Details Rainier Communications on behalf of Classiq Michelle Allard McMahon classiqPR@rainierco.com Merrill Freund on behalf of QuEra +1 415-577-8637 press@quera.com Company Website http://www.classiq.io/

July 23, 2024 08:00 AM Eastern Daylight Time

BestGrowthStocks.Com Issues Analysis on the Next Beneficiaries of the AI Revolution

SoundHound AI Inc.

NEW YORK, NY / NewsDirect / July 22nd, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of SoundHound AI, Inc. a pioneer in advanced voice-enabled AI and conversational intelligence technologies and a comprehensive analysis of the next beneficiaries of the AI revolution. SoundHound AI, Inc. (NASDAQ: SOUN) has garnered significant investor attention following multiple recent announcements that could prove to be significant catalysts for the AI company. Best Growth Stock's full report offers an analysis of SoundHound’s operations, potential upcoming catalysts, growth drivers, financials, share structure, chart, and more. Bonus content “The Next Beneficiaries of the AI Revolution” offers a comprehensive analysis of the next beneficiaries of the AI revolution, which ones stand to benefit near term, and stocks under $15/share to watch within each sector. Access this full analysis and bonus AI report with no obligation: https://bestgrowthstocks.com/soun-analysis/ Access this full analysis and bonus AI report with no obligation: https://bestgrowthstocks.com/soun-analysis/ About SoundHound AI SoundHound AI (Nasdaq: SOUN), a global leader in conversational intelligence, offers voice AI solutions that let businesses offer incredible conversational experiences to their customers. Built on proprietary technology, SoundHound’s voice AI delivers best-in-class speed and accuracy in numerous languages to product creators across automotive, TV, and IoT, and to customer service industries via groundbreaking AI-driven products like Smart Answering, Smart Ordering, and Dynamic Drive Thru, an AI-powered multimodal food ordering solution. Along with SoundHound Chat AI, a powerful voice assistant with integrated Generative AI, SoundHound powers millions of products and services, and processes billions of interactions each year for world class businesses. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.com SOURCE: BestGrowthStocks.Com Contact Details Media Source LLC Steve Macalbry +1 989-274-7778 Editor@bestgrowthstocks.com

July 22, 2024 07:00 AM Eastern Daylight Time

Image

Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share exciting news about a significant achievement for the company. Tonix Pharmaceuticals has been awarded a potential contract worth up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. This contract aims to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections, thereby enhancing the medical readiness of military personnel in biological threat environments. Dr. Lederman explained that Tonix’s program will concentrate on the optimization and development of its TNX-4200 program. The goal is to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families through extensive preclinical evaluation. The program is expected to establish essential physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug (IND) submission, ultimately funding a first-in-human Phase 1 clinical study. The agreement with DTRA is a strategic move to address the DoD’s objective of protecting U.S. Joint Forces from potential biological weapon threats. The DoD announced in December 2022 that it aims to move beyond the traditional ‘one bug, one drug’ approach and is seeking broad-spectrum drugs, as predicting which viruses or how many may be deployed in a biological threat scenario is challenging. Dr. Lederman emphasized that the collaboration with DTRA underscores Tonix Pharmaceuticals' commitment to advancing medical readiness and protection for military personnel. By developing a broad-spectrum antiviral agent, Tonix aims to provide a versatile and robust solution to potential viral threats, enhancing the preparedness and resilience of the U.S. military in diverse and unpredictable biological threat environments. The TNX-4200 program’s focus on creating an effective, orally available antiviral agent highlights Tonix’s innovative approach to addressing complex medical challenges. The successful development of this broad-spectrum antiviral could significantly impact the way viral infections are managed in military and potentially civilian populations, offering a proactive measure against a wide array of viral threats. Tonix Pharmaceuticals continues to be at the forefront of medical innovation, dedicated to developing cutting-edge solutions that meet the evolving needs of the healthcare and defense sectors. The support from the DoD through this substantial contract is a testament to the potential and importance of Tonix’s TNX-4200 program in safeguarding the health and readiness of military personnel against biological threats. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 19, 2024 12:48 PM Eastern Daylight Time

Video

1 2 3 4 5 ... 198

Back